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ABSTRACT
Background: In respiratory syncytial virus (RSV)
bronchiolitis, neutrophils account for .80% of cells
recovered from the airways in bronchoalveolar lavage
(BAL) fluid. This study investigated neutrophil activation
and Toll-like receptor (TLR) expression in the blood and
lungs of infants with severe RSV bronchiolitis.
Methods: BAL fluid and (blood) samples were collected
from 24 (16) preterm and 23 (15) term infants ventilated
with RSV bronchiolitis, and 12 (8) control infants. Protein
levels and mRNA expression of CD11b, myeloperoxidase
(MPO) and TLRs 2, 4, 7, 8 and 9 were measured in
neutrophils.
Results: Blood neutrophils had more CD11b in preterm
and term infants with RSV bronchiolitis than control
infants (p,0.025) but similar amounts of MPO. BAL fluid
neutrophils from infants with RSV bronchiolitis had greater
amounts of CD11b and MPO than blood neutrophils and
BAL fluid neutrophils from controls (p,0.01). Blood
neutrophils from term infants with RSV bronchiolitis had
less total TLR4 protein than preterm infants with RSV
bronchiolitis (p=0.005), and both had less than controls
(p,0.04). Total TLR4 for each group was greater in BAL
fluid neutrophils than in blood neutrophils. Blood
neutrophils from preterm infants with RSV bronchiolitis
had greater TLR4 mRNA expression than term infants
with RSV bronchiolitis (p=0.005) who had similar
expression to controls (p=0.625).
Conclusions: In infants with severe RSV bronchiolitis,
neutrophil activation starts in the blood and progresses as
they are recruited into the airways. Total neutrophil TLR4
remains low in both compartments. TLR4 mRNA
expression is unimpaired. This suggests that neutrophil
TLR4 expression is deficient in these infants, which may
explain why they develop severe RSV bronchiolitis.
Respiratory syncytial virus (RSV) bronchiolitis is
the commonest cause of lower respiratory tract
infection in children under the age of 1 year.
1
Symptoms begin in the upper airways and it is
likely that the primary site of RSV infection is the
nasal epithelium
2 with local spread to the lower
airways.
3 Initial infection of the airways leads to
production of pro-inflammatory cytokines
45 and
chemokines
6 which initiates the recruitment of
inflammatory cells from the peripheral circulation.
There is little evidence that RSV causes a viraemia,
7
but the immunopathogenesis of RSV bronchiolitis
is poorly understood. By studying cells from the
blood and airways of infants with RSV bronchio-
litis and comparing them with uninfected controls,
information can be elucidated about the changes
that inflammatory cells undergo as they are
recruited to the airways.
The clinical spectrum of RSV infection is wide,
from a mild upper respiratory tract infection to
severe lower respiratory tract infection.
1 Risk
factors for severe RSV bronchiolitis are prematur-
ity (particularly with associated chronic lung
disease),
8 congenital heart disease
9 and immuno-
deficiency.
10 Half of infants ventilated for RSV
bronchiolitis are born at term with no risk
factors.
11 1In previous studies we have consistently
shown that term infants have a more vigorous
immune response to RSV infection in their airways
than preterm infants,
451 2and this may relate to
the considerable maturation that occurs in the
third trimester and in the first year of life.
13 14
Neutrophils are the predominant cell found in
the inflammatory infiltrate of the bronchoalveolar
lavage (BAL) fluid of infants ventilated for severe
RSV bronchiolitis.
5 They are recruited to the lungs
early in the course of infection where they are
known to release cytokines
12 and show delayed
apoptosis.
15 16 As the clinical condition improves,
lower neutrophil concentrations are found in the
BAL fluid.
45Neutrophil activation can be studied
by looking at cell surface markers such as the
integrins CD11b or internal markers such as
myeloperoxidase (MPO) found in the neutrophil
granules. Integrin expression is quickly upregulated
by mobilisation of internal stores. MPO is released
to the cell surface when the neutrophil is degra-
nulating at the site of active inflammation.
Toll-like receptors (TLRs) recognise viral and
bacterial pathogen-associated molecular patterns
and initiate a specific inflammatory response to a
range of infections.
17 In RSV infection, TLRs may
play an important role in regulating innate and
adaptive immune responses.
18–20 Immune responses
mature with gestation and during the first few
months of life when infants encounter RSV
infection.
21
Circulating neutrophils express all human TLRs
except TLR3,
22 but the contribution of TLRs to the
pathogenesis of RSV disease is not fully under-
stood. There has been considerable interest in the
role of TLR4 in regulating RSV infection since RSV
F protein has been reported to be a ligand for
TLR4.
23 A clinical study found increased TLR4
expression in blood monocytes of infants with
RSV bronchiolitis,
24 and a genetic susceptibility
study identified two common TLR4 gene muta-
tions which are associated with an increased risk of
severe RSV bronchiolitis compared with mild
disease (odds ratio 5.1 (95% confidence interval
(CI) 1.4 to 18.1) and 4.0 (95% CI 1.3 to 12.5).
25
Intracellular TLRs (3, 7, 8 and 9) recognise viral
and bacterial nucleic acid in the endosomes of
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TLR9 signalling pathways in plasmacytoid dendritic cells,
resulting in significant reductions in type I interferon produc-
tion.
20 RSV may also induce cytokine secretion and mucus
production in airway epithelial cells via TLR3 signalling.
26
We have undertaken a large study to investigate neutrophil
activation and TLR expression in the blood and BAL fluid of
infants with severe RSV bronchiolitis (term and preterm)
compared with control infants to delineate what changes occur
in neutrophils as they migrate to the lungs from the systemic
circulation.
METHODS
Study population and sample collection
Forty-seven consecutive infants aged ,1 year admitted with
severe RSV bronchiolitis to the intensive care unit at Royal
Liverpool Children’s Hospital, Alder Hey over three winter
seasons were recruited to the study. RSV bronchiolitis was
confirmed by direct immunofluorescence of nasopharyngeal
aspirates. After informed consent, samples of peripheral blood
and BAL fluid were collected as previously described.
451 2We
recruited 24 participants who were born prematurely
(,37 weeks gestation) and 23 who were born at term
(>37 weeks gestation). Data from infants born at term were
analysed separately from those infants born preterm. Infants
with underlying cardiorespiratory disease were excluded. The
control group comprised 12 uninfected healthy infants of the
same age as the infants with RSV bronchiolitis who had been
ventilated prior to elective non-cardiac surgery, from whom
blood and BAL fluid samples were collected immediately after
induction of anaesthesia and intubation of the airway. No
recruited infant was subsequently withdrawn from the study.
All samples were processed and data analysed from each
recruited infant. During the first year of the study we collected
BAL fluid but not blood samples.
Preparation of BAL fluid samples
Standard techniques were used to assess total and differential
cell counts.
891 62 7Briefly, BAL fluid was filtered (60 mm pore size
gauze; Sefar Nitex 03-48/31, Sefar, Switzerland) to remove bulk
mucus and then centrifuged. The supernatant was removed and
stored at 270uC. The cellular component was resuspended in
RPMI 1640 and the neutrophils purified using sedimentation
gradient techniques on PolymorphPrep (Axis-Shield PoC AS,
Norway). We took 59 BAL fluid samples, 47 from infants with
RSV bronchiolitis (24 preterm and 23 term infants) and 12 from
healthy control infants. The number of cells was highest in
those infants with RSV bronchiolitis born at term and, as in
previous studies,
451 2 neutrophils were the predominant cell
(table 1). After enrichment, .93% of the cells were neutrophils
with .94% viability; the median (SD) percentages of other cells
were macrophages 4 (3)%, lymphocytes 2 (1)%.
Preparation of blood neutrophils
Neutrophils were purified from whole blood by sedimentation
gradient as described above. Thirty-nine blood samples were
taken, 31 from infants with RSV bronchiolitis (16 preterm and
Table 1 Characteristics of patients and bronchoalveolar lavage (BAL) fluid and blood samples before
enrichment
Infants with bronchiolitis
Control infants Preterm Term
Clinical information
No of patients 24 23 12
Median (range) age on admission
(weeks)
3.5 (25 to 11.7) 16 (4–56) 12 (6–20)
Weight on admission (kg) 3.3 (0.35) 5.1 (0.36) 4.3 (2.0)
Median (range) gestation at birth
(weeks)
34 (27–36) 40 (39–42) 40 (37–40)
BAL fluid cell counts
Total cell concentration
(610
6 cells/ml)
1.8 (0.8) 1.9 (0.5) 1.5 (0.8)
Total cell count (610
6) 4.5 (1) 4.8 (1.2) 3 (0.5)
Percentage of viable cells 95 (2.5) 94 (2) 95 (1)
Median (range) percentage
neutrophils
84 (2.5) 83 (2) 37 (3)
Median (range) percentage alveolar
macrophages
12.5 (1.5) 11.6 (1.0) 47 (3)
Median (range) percentage
lymphocytes
5 (0.5) 3.5 (1.0) 7 (3)
Blood cell counts
No of patients 16 15 8
Total cell concentration
(610
9 cells/l)
9.95 (1.67) 9.95 (1.64) 9.44 (1.5)
Percentage of viable cells 97 (2) 96 (1) 96 (1)
Mean concentration
(610
9/l neutrophils)
4.93 (1.46) 5.11 (1.48) 4.5 (1.56)
Mean concentration
(610
9/l monocytes)
0.99 (0.15) 1.11 (0.17) 1.0 (0.18)
Mean concentration
(610
9/l lymphocytes)
3.67 (0.3) 3.57 (0.44) 3.63 (0.35)
Mean concentration
(610
9/l eosinophils)
0.088 (0.04) 0.078 (0.029) 0.082 (0.045)
Data mean (SEM) unless stated otherwise.
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difference in the total cell count between cases and control
infants (table 1). After enrichment, .95% of the cells were
neutrophils with .96% viability; the median (SD) percentages
of other cells were monocytes 2 (1)%, lymphocytes 2 (1)%.
FACS analysis: protein expression of CD11b, MPO and TLRs 2, 4,
7, 8 and 9
All cells for FACS analysis were triple stained with ethidium
monoazide bromide (EMA) (Biotium, UK) to allow exclusion of
non-viable cells, a neutrophil marker (MPO or CD16) and the
test antibody (TLRs 2, 4, 7, 8, 9, CD11b, MPO) or isotype
control.
For cell surface expression of CD11b, TLR2 and TLR4
neutrophils were labelled and fixed (BD cytofix: 1% parafor-
maldehyde).
For total expression of CD11b, MPO and TLRs 2, 4, 7, 8 and 9
neutrophils were permeabilised, fixed (BD Cytofix and
Cytoperm; BD Biosciences, Oxford, UK) and labelled. Samples
were analysed on a FACSort flow cytometer (Becton Dickinson)
collecting a minimum of 10 000 events. Data were processed
using WinMDI Version 2.8. Neutrophils were gated by size,
granularity, viability and CD16 or MPO expression. TLR
expression was standardised from the mean fluorescent intensity
(MFI) into antigen binding capacities (ABC) relative units
28 to
allow quantification of the antigen binding sites between
different commercial antibodies, each with different binding
affinities, according to the manufacturer’s instructions (Simple
Cellular Antigen-Bangs Laboratories, Kidlington, UK) (table 2).
Real-time polymerase chain reaction (RT-PCR)
RNA was prepared from 0.5610
6 neutrophils using Trizol
(Gibco, Basingstoke, UK), 5 mg of DNAse-treated total RNA
was used as a template for first strand cDNA synthesis in a
20 ml reaction using Multiscribe reverse transcriptase (Applied
Biosystems, Foster City, California, USA).
The mRNA expression of TLRs 2, 4, 7, 8 and 9 was assessed
using Taqman primer/probe sets (Applied Biosystems). All PCR
reactions were in triplicate using an Applied Biosystems 7300
and standardised to the housekeeping gene L32 using the DCt
method.
Statistical analysis
Protein expression of CD11b, MPO and protein and mRNA
expression of TLRs 2, 4, 7, 8 and 9 were compared from enriched
neutrophil blood and BAL fluid samples in preterm and term
infants with RSV bronchiolitis and controls. Differences in
means between patient groups were examined using one-way
analysis of variance and independent sample t tests. As paired
data were not available on all infants for comparison of the
same neutrophils in blood and BAL fluid, pairing was ignored
leading to more conservative analyses, but an analysis using
only paired data is available in table 3 in the online supplement.
Data were analysed using SPSS Version 15 (SPSS, Chicago,
Illinois, USA). A probability level of 95% (p,0.05) was
considered as the threshold for statistical significance.
RESULTS
Protein expression of neutrophil activation markers in infants
with RSV disease
All neutrophils in the blood and BAL fluid were positive for
CD11b and MPO expression. All data presented are expressed as
mean (SEM) relative ABC units (610
6). The amounts of CD11b
in blood neutrophils from both preterm and term infants with
RSV bronchiolitis (0.05 (0.005) and 0.055 (0.005), respectively)
were greater than in control infants (0.02 (0.005), p,0.025).
The amounts of CD11b in BAL fluid neutrophils in preterm and
term infants with RSV bronchiolitis (0.08 (0.001) and 0.07
(0.002), respectively) were greater than in controls (0.025
(0.005), p,0.012; fig 1A and B).
There was no difference between preterm and term infants
with RSV bronchiolitis and controls in the amount of blood
neutrophil MPO (0.15 (0.03), 0.12 (0.02) and 0.13 (0.01),
respectively; p.0.05). The amount of MPO was greater in
BAL fluid neutrophils from both preterm and term infants with
RSV bronchiolitis (0.28 (0.02) and 0.30 (0.02), respectively) than
from control infants (0.14 (0.01); p,0.05; fig 1C). There were
no significant differences in the expression of CD11b or MPO
between preterm and term infants in blood or BAL fluid
neutrophils. For both groups of infants with severe RSV
bronchiolitis, there were greater amounts of CD11b and MPO
in neutrophils from the BAL fluid than from the blood. There
was no difference between these compartments for either
marker in control infants.
Expression of TLRs in infants with RSV bronchiolitis and controls
All neutrophils in the blood and BAL fluid were positive for
expression of TLRs 2, 4, 7, 8 and 9. There was no difference
between cell surface TLR2 expression on neutrophils from blood
or BAL fluid or between preterm, term or control infants (fig 2A,
B), nor was there any difference between groups or compart-
ments for total TLR2 (fig 2A, C). There was no difference in
neutrophil cell surface TLR4 expression between the three
groups in either the blood or the BAL fluid (fig 3A, B). However,
in blood neutrophils the total TLR4 for term infants with RSV
bronchiolitis was significantly less than for preterm infants
with RSV bronchiolitis (0.51 (0.023) vs 0.70 (0.038), p=0.036),
and both were less than for control infants (1.0 (0.035),
p=0.005; fig 3B).
In the BAL fluid, total neutrophil TLR4 was significantly less
in term infants with RSV bronchiolitis than in preterm infants
with RSV bronchiolitis (0.70 (0.02) vs 0.92 (0.02), p=0.03), and
both were less than in control infants (1.70 (0.028), p=0.001;
fig 3A, C). For each patient group there was significantly more
total neutrophil TLR4 expressed in the BAL fluid than in the
blood (p,0.05).
For the TLRs expressed intracellularly (TLRs 7, 8 and 9) there
was considerably less overall expression in neutrophils from
blood and BAL fluid than those expressed on the cell surface
Table 2 Antibodies used for flow cytometry
Antibody type Manufacturer
Antibody raised against
TLR2 FITC mouse monoclonal IgG2a Imgenex
TLR4 FITC mouse monoclonal IgG2a
TLR7 FITC mouse monoclonal IgG1
TLR8 FITC mouse monoclonal IgG1
TLR9 FITC mouse monoclonal IgG1
CD16 PE mouse monoclonal IgG1 BD BioSciences
MPO PE mouse monoclonal IgG1 DakoCytomation
CD11b FITC mouse monoclonal IgG1 BD Biosciences
Isotype antibodies
FITC/PE mouse IgG1 control Imgenex
FITC/PE mouse IgG2a control
MPO, myeloperoxidase.
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neutrophil activation markers is
upregulated in respiratory syncytial virus
(RSV) disease. Data are presented as
mean (SEM) arbitrary units of antigen
binding capacity (ABC) 610
6.
(A) Histograms of flow cytometry data
from two representative patients, an
infant with RSV bronchiolitis (left) and a
control infant (right), showing the mean
protein expression of CD11b in the
bronchoalveolar lavage (BAL) fluid
compared with isotype control (shaded)
(B) To determine mean cell surface
CD11b expression, blood and airway
neutrophils were stained, fixed and
analysed by flow cytometry. CD11b
expression was similar for term (n=15)
and preterm infants (n=16) with RSV
bronchiolitis, and both were significantly
greater than controls (n=8). There was
significantly greater cell surface CD11b
protein expression in the BAL neutrophils
than in the blood neutrophils. (C) To
determine mean total myeloperoxidase
(MPO) expression, neutrophils from blood
and BAL fluid were fixed and
permeabilised before staining and
analysed by flow cytometry. For blood
neutrophils there was no difference in
protein expression of MPO between
infants with bronchiolitis (n=31) and
controls (n=8). For the BAL fluid
neutrophils, both term (n=15) and
preterm infants (n=16) with RSV
bronchiolitis had significantly more MPO
expression than control infants (n=8).
There was significantly more MPO in BAL
fluid than in blood. *p,0.05.
Figure 2 Toll-like receptor (TLR) 2 protein expression is unaltered in infants with severe respiratory syncytial virus (RSV) bronchiolitis. All data presented as
mean (SEM) arbitrary units of antigen binding capacity (ABC)610
6. (A) Representative histograms from flow cytometric staining of TLR2 on bronchoalveolar
lavage (BAL)fluid neutrophils from three infants, a preterm infant with RSV bronchiolitis, a term infant withRSV bronchiolitis and a control infant. (B) The mean
expression of cell surface TLR2 was determined by staining and fixing neutrophils prior to analysis by flow cytometry. The mean expression of cell surface
TLR2wassimilarbetweenallthreepatientgroupsforairwayandbloodneutrophils(preterminfants,n=16;terminfants,n=15;controls,n=8)andforea ch
group between blood and BAL fluid neutrophils. (C) To determine total TLR2, the neutrophils were fixedand permeabilised prior to analysis by flow cytometry.
Total neutrophil TLR2 was similar between all three patient groups in both blood and BAL fluid (preterm RSV, n=16; term RSV, n=15; control, n=8) and
between blood and BAL fluid for each group.
Paediatric lung disease
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982–9070 compared with the much higher range of total TLR2
and TLR4 of 0.138–1.7610
6. There were no significant
differences in neutrophil expression of the intracellular TLRs
7, 8 and 9 between term and preterm infants with bronchiolitis
and controls in either blood or BAL fluid neutrophils or between
BAL fluid and blood within each group (data not shown).
Neutrophil expression of TLR mRNA in infants with severe RSV
bronchiolitis compared with healthy infants
In the blood, neutrophil mRNA expression for TLR4 was similar
for term infants with RSV bronchiolitis and control infants
(34.84 (2.168) and 48.16 (2.758), respectively, p=0.625; data
expressed as mean (SEM) logfold ratio of TLR mRNA to L32
mRNA). Blood neutrophil TLR4 mRNA expression of preterm
infants with RSV bronchiolitis (566.27 (19.825)) was much
greater than that of term infants with RSV bronchiolitis
(p=0.005) or controls (p=0.021; fig 4A).
In the BAL fluid, neutrophil TLR4 mRNA expression was
significantly less than in the blood for each patient group.
Similarly, BAL fluid neutrophil mRNA expression for TLR4 was
greater for preterm infants with RSV bronchiolitis (4.38 (0.122))
than for term infants with RSV bronchiolitis (2.46 (0.129),
p=0.037) and for controls (1.12 (0.577), p=0.034). As in the
blood, BAL fluid neutrophil TLR4 mRNA expression for term
infants with RSV bronchiolitis was similar to that of controls
(p=0.6, fig 4B).
To determine if the increased expression of TLR4 mRNA in
the blood compared with the BAL fluid was also observed for
the other TLRs, the mean mRNA expression of TLRs 2, 7, 8 and
9 in blood neutrophils for the two groups with RSV
bronchiolitis and the control group was measured (fig 4C). For
TLR7 and 9 there was a similar pattern of greatly increased
neutrophil mRNA expression in preterm infants with RSV
bronchiolitis compared with the other two groups. Neutrophil
TLR7 mRNA was undetectable in controls. There were only low
and similar levels of expression of neutrophil TLR2 in the three
groups and of TLR8 mRNA in term infants with RSV
bronchiolitis and controls (p.0.05). There was no detectable
expression of neutrophil TLR8 mRNA in preterm infants with
RSV bronchiolitis. In the BAL fluid there was very little
neutrophil mRNA expression of TLRs 2, 7, 8 and 9 compared
with blood (data not shown).
DISCUSSION
This study has shown for the first time that neutrophils from
infants with severe RSV bronchiolitis are activated both in the
peripheral circulation and, to a greater degree, in the lower
airways. This was associated with reduced neutrophil TLR4 in
both compartments, with the lowest amounts for term infants
with RSV bronchiolitis. The expression of neutrophil TLRs 2, 7,
8 and 9 in both blood and BAL fluid was similar in all three
groups. This finding of reduced TLR4 protein expression raises
the possibility of an impaired innate immune response and
contrasts with findings of many clinical studies which have
shown highly overexuberant inflammatory responses during
RSV bronchiolitis. This is the first study to investigate the role
of TLRs in both the airway and circulation of infants with RSV
bronchiolitis. We studied the expression of the human TLRs
currently believed to be involved in viral recognition in a group
of infants with the most severe manifestations of RSV disease
and no known risk factors. We analysed infant neutrophils, the
biology and immune function of which is very different from
neutrophils of adults.
29
This work has some limitations. First, as only infants with
severe disease were intubated, we were unable to collect BAL
fluid samples from infants with mild or moderate disease to
determine whether these changes were more marked with
Figure 3 Toll-like receptor (TLR) 4 protein expression is downregulated in infants with severe respiratory syncytial virus (RSV) bronchiolitis. Data
presented as mean (SEM) arbitrary units of antigen binding capacity (ABC)610
6. (A) Representative histograms from flow cytometric staining of TLR4
on bronchoalveolar lavage (BAL) fluid neutrophils from three infants, a preterm and a term infant with RSV bronchiolitis and a control infant. TLR4
expression was greater than TLR2. For TLR4, term infants with bronchiolitis had less total TLR4 than preterm infants with bronchiolitis and control
infants. Shaded histograms are isotype controls. (B) Expression of cell surface TLR4 was analysed by flow cytometry after staining and fixing
neutrophils. There was no significant difference between patient groups for cell surface expression of neutrophil TLR4 for either BAL fluid neutrophils
(preterm RSV, n=24; term RSV, n=23; controls, n=12) or blood neutrophils (preterm RSV, n=16; term RSV, n=15; controls, n=8) or between
blood and BAL fluid neutrophils for each patient group. (C) To determine total neutrophil TLR4 expression, cells were fixed and permeabilised before
analysis by flow cytometry. In both blood and BAL fluid neutrophils, term and preterm infants with RSV bronchiolitis had significantly less TLR4
expression than control infants. Term infants with RSV bronchiolitis had significantly less total TLR4 than preterm infants with bronchiolitis (p=0.03).
*p,0.05. Total neutrophil TLR4 in BAL fluid was significantly greater (p,0.05) than in blood for all three groups (not shown).
Paediatric lung disease
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studies.
25 Second, although our findings may suggest a
constitutive reduction in neutrophil TLR4 expression in some
infants, we do not know whether expression was altered before
the onset of RSV disease or after recovery. RSV F protein has
been shown to bind to TLR4 on monocytes,
30 and we have some
preliminary data which suggest that the RSV virus may bind to,
or associate with, neutrophils in the BAL fluid of RSV-infected
infants. Whether this results from an interaction between RSV
and a specific receptor such as TLR4 has not been determined.
We have undertaken some preliminary in vitro work with
neutrophils from healthy adults which shows no evidence of
interference by RSV with TLR4 antibody binding or TLR4
detection in our assay. Additional evidence to suggest that RSV
F protein binding is not interfering with TLR4 detection is
provided by the observation that TLR4 expression on the
surface of neutrophils was similar between our three groups and
between the blood and the BAL fluid within the groups,
whereas there are differences for these comparisons in total
TLR4 expression.
As the neutrophils from the peripheral circulation of infants
with severe RSV bronchiolitis expressed higher levels of CD11b
than uninfected controls, although recirculation from the lung
cannotbeexcluded,itappearsthattheybecomepartiallyactivated
or primed in the peripheral circulation before recruitment into the
lung. In the lung, neutrophils express higher levels of total and cell
surface CD11b and MPO, which suggests either progressive
activation
31–33 and release of intracellular MPO by degranulation
at this site or, alternatively, the selective recruitment of highly
activated neutrophils from the peripheral circulation.
The observed decrease in neutrophil intracellular TLR4
protein expression could be due to reduced synthesis, mobilisa-
Figure 4 Neutrophil TLR4 mRNA expression predominantly occurs in the blood compared with the bronchoalveolar lavage (BAL) fluid and is similar in
term and control infants. Data presented as mean (SEM) logfold ratio after expression of mRNA assessed by RT-PCR for all Toll-like receptors (TLRs)
standardised as a ratio to mRNA for the housekeeping gene L32. (A) Neutrophil TLR4 mRNA was significantly increased in blood neutrophils, mRNA
expression was greater in preterm infants (n=16) than in term infants with respiratory syncytial virus (RSV) bronchiolitis (n=15), but there was no
significant difference between term infants with RSV bronchiolitis and controls (n=8). (B) Neutrophil TLR4 mRNA was significantly increased in BAL
fluid neutrophils from preterm infants with RSV bronchiolitis (n=16) compared with term infants with RSV bronchiolitis (n=15), which was similar to
control infants (n=8). There was considerably less mRNA TLR4 for each patient group in the BAL fluid than in the blood (not shown). (C) As the blood
seemed to be the main site of TLR4 mRNA production, neutrophil mRNA expression of TLR 2, 7, 8 and 9 was determined for blood neutrophils for
preterm (n=16) and term infants with RSV bronchiolitis (n=15) and for controls (n=8). There was no significant difference in the expression of
blood neutrophil mRNA TLR2 between the three patient groups. Preterm infants had significantly greater expression of TLR7 and 9 in blood neutrophils
than term or control infants (p,0.05). The low levels of expression of neutrophil TLR8 in term infants with RSV bronchiolitis were similar to the levels in
control infants; levels of TLR8 in preterm infants with RSV bronchiolitis were undetectable. *p,0.05.
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Thorax 2009;64:798–805. doi:10.1136/thx.2008.107821 803tion to the cell surface or increased degradation. The first two of
these seem unlikely as, compared with controls, neutrophil
TLR4 mRNA expression was greatly increased in preterm and
similar in term infants and TLR4 expression on the surface of
neutrophils was similar between the three groups. A precedent
for TLR4 degradation comes from epithelial cells where TLR4/
MD2 complexes are degraded once engaged by an agonist.
34 The
third explanation alone seems unlikely as neutrophil TLR4 was
not only reduced in BAL fluid neutrophils—where RSV is
present in large titres—but also on blood neutrophils. There is
currently no evidence to suggest that RSV causes a viraemia.
7
As only the expression of TLR4 and not of other TLRs is
markedly reduced in the main infiltrating inflammatory cell
during active infection, this suggests both a specific effect on
TLR4 expression and that neutrophils and TLR4 play an
important role in host defence against RSV infection. TLR4
signalling has primarily been studied in airway epithelial cells
during RSV infection. There is very little work on RSV infection
and TLR pathways in blood-derived cells and none, to our
knowledge, in clinical studies that investigated neutrophils.
Deficiencies in TLR pathways have been shown to be important
in other viral infections and modulate host defence—for
example, the Vaccinia virus protein A46R blocks TLR4 signal-
ling
35 in human epithelial tumour cell lines (HeLA cells) and
Vaccinia virus lacking A46R has attenuated virulence.
One of the striking findings of our study was that, in
neutrophils of preterm infants with RSV bronchiolitis compared
with controls, despite reduced protein expression of neutrophil
TLR4 in the blood and BAL fluid, there were vastly increased
levels of TLR4 mRNA in the blood. In preterm infants this may
represent immaturity of the TLR4 transcription pathway.
However, in previous unpublished studies we have measured
mRNA for TLRs 2, 4, 7 and 9 in two groups of controls (those
born at term and those born preterm) and found no differences
in expression between the groups. In the preterm infants this
may represent an appropriate response to RSV infection with
increased degradation and utilisation of TLR4-dependent path-
ways to help clear the infection, or these findings may reflect
the immunological immaturity of these infants. As the
expression of TLRs has been shown to increase with gestational
age,
21 the finding that total neutrophil TLR4 is much less in
term infants than in preterm infants with severe RSV disease
may suggest that term infants with severe disease have a
constitutive abnormality in TLR4 expression. This may be
related to the genetic polymorphisms in TLR4 that are
associated with an increased risk of severe disease
24 25 and with
impaired TLR4 signalling in response to RSV F protein.
27
This study has highlighted important aspects about the role of
neutrophils in RSV disease and the differences in the immuno-
pathogenesis in preterm and term infants. In vitro studies are
needed to determine whether the abnormalities in TLR4 expres-
sioncontributetoor are a resultof RSVdisease.TLR4 agonists are
currently undergoing phase II clinical trials, so elucidating these
mechanisms further will have important therapeutic implications
for infants with severe RSV bronchiolitis.
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